Aerie Pharma downgraded by Cantor Fitzgerald with a new price target

8/23/22 7:09:23 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Cantor Fitzgerald downgraded Aerie Pharma from Overweight to Neutral and set a new price target of $15.25 from $30.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AERI

Date	Price Target	Rating	Analyst
8/29/2022	$14.00 → $15.25	Buy → Neutral	Citigroup
8/23/2022		Buy → Hold	Needham
8/23/2022	$30.00 → $15.25	Overweight → Neutral	Cantor Fitzgerald
2/25/2022	$22.00 → $14.00	Buy	Needham
11/5/2021	$24.00 → $22.00	Buy	Needham
8/5/2021	$26.00 → $24.00	Buy	Needham